|
By: Josh Sloat
Join me in SF or Online
We're excited to share that we've been invited to host an IP workshop at this year's InnovatorMD World Congress. This is the largest physician innovation event and provides access to top-tier health innovation education, innovation ecosystem networking, and all the CME you need for the year. You can see the full agenda here.
Time and location: Aug 17-20, both online and SF Bay Area About the Workshop
Illustration: Declan Wrede
Top 3 Inventor Mistakes and How to Avoid Them
A critical rescue line to future self The patent world is full of trap doors that lie waiting for unsuspecting inventors. Some of these mistakes are reversible with limitations. Others have no undo button. In this talk, we will cover the most common patenting mistakes made by inventors and startups. We’ll highlight best practices for not making the mistakes in the first place and explore available remedial options. Topics include public disclosure mishaps, prior art searching consequences, and ownership quagmires. Time and location: Thursday, August 18, 2022 | 2:00 PM - 3:30 PM PT | Live via Zoom and in-person Network Discount
For a 50% discount, use code SPEAKERREF when checking out.
About InnovatorMD
InnovatorMD's mission is to globally advance the work of physician innovators and entrepreneurs delivering solutions that revolutionize patient care. They are a group of physician innovators from various backgrounds with a single vision - to spread physician innovation to the rest of the world and to have a positive impact on patient outcomes and physician wellness while moving the healthcare industry forward.
0 Comments
By:Josh Sloat
Welcome aboard
We're excited to announce that we're welcoming Ty F. Davis to the growing Aurora family! Ty joins us this summer, starting his role as a Patent Strategy Associate. Ty's blend of hands-on, real world startup experience as an engineer and IP practitioner, combined with his kind, laid back, and deeply empathetic personality make him a perfect fit for Aurora and her clients. He will actively be working in the areas of patent portfolio management and educational content development.
Mechanical and Energy Expertise. Ty holds a Bachelor of Science in Mechanical Engineering from The New Mexico Institute of Mining and Technology, where he also designed systems for the rocket sled track where the land-based speed record for a vehicle was set (Mach 8.5!). Throughout his career, Ty has worked as a product development engineer, managing member, and patent agent in energy sector startups. This experience included electro-mechanical automation development, firmware development, and remote telemetry solutions. Inventor First. In addition to founding his own start-up to develop methane-emission reducing technologies, as an inventor, Ty has two issued patents and is actively pursuing several more. This experience, combined with his business and IP acumen, allows him to communicate with inventors with a level of precision and empathy like few practitioners can.
By: Josh Sloat
Prenuptial Patenting
Responsible Engagement with Engineering Firms
You have your big idea and now it’s time to breathe it into existence, but you need some help with the development. Like many others, you may turn to the aid of an engineering firm or dev shop. This relationship is a marriage of sorts. But it’s a marriage that is designed to inevitably end in divorce! How cleanly, smoothly, and successfully this separation goes depends on the steps that you take before it officially begins. Both parties come to the relationship with existing assets – IP, software, prototypes, ideas, documentation, etc. More will be created collaboratively throughout the course of the relationship. But how do you ensure you exclusively get back out what you came with and also get what you contributed and uniquely paid for? In this month’s episode, Dr. Ashley Sloat, President and Director of Patent Strategy here at Aurora, leads a discussion into Responsible Engagement with Engineering Firms, or what we affectionately refer to here as “Prenuptial Patenting”. Ashley and our all star patent panel walk you down the aisle and explore everything you need to know to experience marital bliss and an amicable divorce with your engineering partners. This talk covers the full life cycle from vetting partners to post development concerns and everything in between – with particular focus on relationship complexities like IP ownership, assignment from engineering firm inventors back to you, and how to avoid the traps of viral IP. Ashley is also joined today by our always exceptional group of IP experts including: ⦿ Kristen Hansen, Patent Strategist at Aurora ⦿ David Jackrel, President of Jackrel Consulting Availability
Patently Strategic is available on all major podcasting directories, including Apple Podcasts, Spotify, and Google Podcasts. We're also available on 12 other directories including Stitcher, iHeart Radio, and TuneIn, so you should be able to find us wherever you listen to podcasts.
Topic and guest participant requests
If you’re an agent or attorney and would like to be part of the discussion or an inventor with a topic you’d like to hear discussed, please reach out.If you’re an agent or attorney and would like to be part of the discussion or an inventor with a topic you’d like to hear discussed, please reach out.
Resources
By: Josh Sloat
Fortifying Life Science Patents
Eligibility and Enablement – Sections 101 and 112
The life sciences are currently faced by at least two major plagues in our patent world. The first is that many life science innovations have been deemed ineligible in terms of patentable subject matter. In other words, the courts and the patent office believe that the patent laws are not meant to protect these innovations. The second plague is that the courts believe that many life sciences patents are not enabled. In other words, they are not described in sufficient detail to enable one of skill in the art to make and use the invention. These subject matter eligibility and enablement plagues manifest in dreaded Section 101 and 112 rejections. The practical implications are staggering:
In this month’s episode, Dr. Ashley Sloat, President and Director of Patent Strategy here at Aurora, leads a discussion, along with our all star patent panel, delving deeply into these rejections. And in the interest of avoiding a podcast 101 rejection, provides some very practical application tips that will help to fortify your life science patent applications. Ashley is joined today by our always exceptional group of IP experts including:
Availability
Patently Strategic is available on all major podcasting directories, including Apple Podcasts, Spotify, and Google Podcasts. We're also available on 12 other directories including Stitcher, iHeart Radio, and TuneIn, so you should be able to find us wherever you listen to podcasts.
Topic and guest participant requests
If you’re an agent or attorney and would like to be part of the discussion or an inventor with a topic you’d like to hear discussed, please reach out.If you’re an agent or attorney and would like to be part of the discussion or an inventor with a topic you’d like to hear discussed, please reach out.
Resources
By:Josh Sloat
Welcome aboard
We're excited to announce that we're welcoming Sophia Hsin-Jung Li to the Aurora family! Sophia joins us this month, starting her role as a Patent Strategy Fellow! Sophia is helping us blaze a new trail by creating our first ever patent strategy fellowship. She will actively be working in the areas of patent portfolio management, educational content development, and internal workflow improvements.
Molecular Biology Expertise. Sophia holds a Doctor of Philosophy in Molecular Biology from Princeton University, specializing in microbiology and biochemistry. Her thesis describes a novel translational control in E. coli under metabolic restrictions. She also published the first protocol for human mitochondrial ribosome profiling. She has a Bachelor of Science double-majoring in Chemical Engineering and Biology from MIT with an emphasis in cancer biology and biophysics. She did her postdoc training in Stem Cell Bioengineering at EPFL in Switzerland, where she developed a tissue-engineered mini-gut for studying host-microbe interactions. Startup enabler. With her expertise in science and technology, she can understand the values of new findings at a deep level and effectively communicate the knowledge to audiences from other backgrounds. Sophia wants to use her technical skills to help startups become successful from the ground up.
By: Josh Sloat
S2 Episode 4: Into the Patentverse Vol. 1
Web 3.0, Blockchain, Cryptocurrency, and NFTs
“Metaverse”. It is the buzziest of the buzzwords in tech today and will soon be joining the ranks of “AI” and “ML” as requisite keywords in the next generation of pitch decks and patent applications. But what are the core components of the Metaverse? And what are their implications in the world of intellectual property? The Patently Strategic Podcast will be exploring this topic over the course of several upcoming episodes. We begin our exploration today with Web 3.0 – the third major iteration of the Internet. While it may prove to be the next great tech revolution, the broad shape and definition of the Metaverse itself is still more firmly baked in science fiction than in commercial tech reality. Many of its core building blocks, however, are likely right in front of our eyes (or headsets, perhaps). History shows that most major technology revolutions are rarely leaps, but instead evolutionary products of incremental steps, composed of many existing building blocks, met with market readiness. The Web 3.0 innovations of blockchain, cryptocurrency, and NFTs that are taking shape in front of us will no doubt be among these essential building blocks. With an ability to touch both our physical and virtual worlds, cryptocurrencies could form the monetary basis for all economic activity in the Metaverse. NFTs make it possible for unique items to exist and assets to be exclusively owned in the digital realm. The very foundations and infrastructure for the Metaverse and its virtual worlds could be built on blockchain technology. Perhaps the Metaverse is simply how we experience the third major phase of the web – or maybe in its purest, most decentralized form, the Metaverse is built entirely on top of it. In any case, it's hard to imagine a future where the two are not inextricably linked. This third phase of the internet also poses some of the most interesting questions for the world of IP. What will the impact be on digital property rights in a secure marketplace, governed by smart contracts? How will copyrights play in digital worlds with their own art and governance? Is there merit in considering a new type of protection category outside of patents and copyrights? In our very first IPWatchdog episode, Kristen Hansen, Patent Strategist and software patent guru here at Aurora, leads a discussion along with our all star patent panel, digging into:
Kristen is also joined today by our always exceptional group of IP experts including:
Availability
Patently Strategic is available on all major podcasting directories, including Apple Podcasts, Spotify, and Google Podcasts. We're also available on 12 other directories including Stitcher, iHeart Radio, and TuneIn, so you should be able to find us wherever you listen to podcasts.
Topic and guest participant requests
If you’re an agent or attorney and would like to be part of the discussion or an inventor with a topic you’d like to hear discussed, please reach out.If you’re an agent or attorney and would like to be part of the discussion or an inventor with a topic you’d like to hear discussed, please reach out.
Resources
By: Josh Sloat
S2 Episode 3: Common Ownership
Whose prior art is it anyway?
In this month's episode, our experts help to demystify the concept of Common Ownership and how it can be leveraged to disqualify prior art that might otherwise cause a rejection during prosecution. Dr. Ashley Sloat, President and Director of Patent Strategy here at Aurora leads this discussion along with our all star patent panel, digging into Common Ownership exceptions, joint research exceptions, and terminal disclaimer practice. And if this all sounds like a foreign language or if you’re wondering why you might care, we include a primer that will help you quickly get up-to-speed on key concepts like inventorship, ownership, assignments, prior art, and terminal disclaimers.
One of the recurring themes of this podcast is helping inventors avoid sharp corners and we’ve found that these concepts in particular trip up a lot of newer inventors and the resulting problems that come from misunderstandings around these core concepts can be difficult to untangle.
Ashley is joined today by our always exceptional group of IP experts including:
Availability
Patently Strategic is available on all major podcasting directories, including Apple Podcasts, Spotify, and Google Podcasts. We're also available on 12 other directories including Stitcher, iHeart Radio, and TuneIn, so you should be able to find us wherever you listen to podcasts.
Topic and guest participant requests
If you’re an agent or attorney and would like to be part of the discussion or an inventor with a topic you’d like to hear discussed, please reach out.If you’re an agent or attorney and would like to be part of the discussion or an inventor with a topic you’d like to hear discussed, please reach out.
Resources
By: Josh Sloat
Patent Award for Startups and Inventors
In 2020 at the height of the COVID-19 crisis, Aurora Consulting announced the RISE Award to help small businesses and inventors through the unprecedented, challenging times. In a time of fighting for survival, we knew that IP strategies could be at risk, but we strongly felt that weathering this crisis should not come at the loss of hard-fought R&D efforts. Consistent with our mission to support emerging growth companies, we came up with the Relief for Innovative Startup Endurance (or RISE) Award to help a selected startup extend their runway by helping them freely secure a provisional patent.
Given how incredibly rewarding the entire experience was and given the problems that still plagued even a year later, we decided to bring the RISE Award back in 2021. Due to the response and circumstances of the times, we expanded the offerings beyond the single $5,000 award to include the addition of $2,500 awards to several other exceptional finalists. Over its first two years, seven startups have received no cost patent assistance from the RISE Award. We dig deeper into the history of the award and how it's helped past recipients in this month's episode of the Patently Strategic Podcast.
Listen to learn more and meet past winners
Recognition for Innovative Startup Excellence
We’re proud to announce that we’re bringing the RISE Award back for 2022 and beyond, as the Recognition for Innovative Startup Excellence Award. We're offering a free provisional U.S. patent application or $5,000 towards a non-provisional U.S. patent application to a selected applicant. We hope that this award will continue to help provide stability and encouragement to diligent innovators.
We're offering a free provisional U.S. patent application or $5,000 towards a non-provisional U.S. patent application to a selected applicant Now taking applications for RISE 2022
We're taking applications starting now and going through May 15th. Listen to the podcast above to learn more about the award and meet past winners. Click the button below to apply using our simple application. You can also sign up for our newsletter if you want to receive updates on this year's award and be notified when future awards become available. Good luck and we can't wait to learn more about you and your innovations!
By: Josh Sloat
S2 Episode 2: Inventor Stories Vol. 1
RISEing with Patents
In this month’s special episode, we’re sharing a great sit down with three very innovative, up-and-coming inventors – as we also launch the next installment of our RISE award. We are joined today by:
These inventors share their stories and provide invaluable tips and advice, much learned the hard way. Along the way, we explore:
Availability
Patently Strategic is available on all major podcasting directories, including Apple Podcasts, Spotify, and Google Podcasts. We're also available on 12 other directories including Stitcher, iHeart Radio, and TuneIn, so you should be able to find us wherever you listen to podcasts.
Topic and guest participant requests
If you’re an agent or attorney and would like to be part of the discussion or an inventor with a topic you’d like to hear discussed, please reach out.If you’re an agent or attorney and would like to be part of the discussion or an inventor with a topic you’d like to hear discussed, please reach out.
Resources
We're also providing computer-generated transcripts for improved accessibility and additional reference opportunities. 2022 RISE Award
The RISE award offers a free provisional U.S. patent application or $5,000 towards a non-provisional U.S. patent application to a selected applicant. We're taking applications until May 1st. If your startup could benefit from this award or you know of another innovator who could, use the button below to learn more and apply.
By: Daniel Wright
Illustration: Declan Wrede
Demystifying Chemical and Drug Patents
Chemical and drug patents employ a style of claim language that can appear daunting and unnecessarily overcomplicated, but the ability to read and make sense of these documents is a necessary skill to develop when navigating the pharmaceutical world. In this article, we’ll break down the underlying complexities and demonstrate how they’re actually motivated by a surprisingly straightforward strategy that synthesizes common chemical nomenclature with standard patent tactics.
The Value of Staking a Claim in the Pharma World
The economics of the pharmaceutical industry demand an immense upfront investment to push a drug program through discovery, clinical trials, the FDA, and only then, into the market. For the most part, the only thing guarding these potential profits is the IP. While, at the end of this process, the drug company is often manufacturing a single compound, the related patents need to have breadth for the same reason as any other industry: slight variations of the compound and/or its formulation as the administered drug can be equally commercially viable and merit protection. On the surface, though, the strategy of how to claim this breadth can appear alien, even to those familiar with patent jargon.
The economics of the pharmaceutical industry demand an immense upfront investment … For the most part, the only thing guarding these potential profits is the IP. Balancing Specificity and Breadth in Patents
The first and most essential construct to understand when reading chemical and drug patents is the “Markush Structure.” But before exploring what that means and how it’s used, it’s helpful to first understand why it comes into play.
For a successful patent, you need specificity and breadth, but moreover, you need your breadth to be specific. Nebulously claiming all possible and wild variants won’t satisfy the Patent Office’s requirement for sufficient detail, and loose claim language may bump into more prior art than you realize. The standard practices of chemical nomenclature present an interesting challenge to patents. On one hand, a structural formula can communicate a very specific molecule. When drawn out, acetone looks like acetone, and taxol looks like taxol. As written, structures can only mean one thing (or a set of isomers when stereochemistry is ignored). On the other hand, generic terms for classes of molecules or functional groups can be profoundly broad. Just try to imagine all the different things you could draw that would fit the descriptor “alkyl-substituted heteroaryl.” Standard Patent Tactic: Markush Groups
Patents across many industries will often employ something called a “Markush group” to specify their variables. Establishing a Markush group always uses the phrase “selected from the group consisting of…” followed by a finite list of options. For example, a claim regarding a plumbing system might state that a particular valve is “selected from the group consisting of a ball valve, a butterfly valve, and a needle valve.” The term “consisting of” limits the options to only what is provided in the list, so in this example, the valve in question could not be a gate valve. Conveniently, you need not define each of these terms of your Markush group in the claim. They can be defined in the specification or assumed, if their meaning is well established in the art.
Chemical Patent Application: Markush Structures
Chemical patents take advantage of the same approach but further synthesize it with a structural formula to form a hybrid that can be considered a “Markush Structure.” These types of claims always begin with a structural formula that includes variables placed throughout (e.g., X, Y, Z, R1, R2, R3, etc.). Down in the body of the claim, each variable will then be defined by a Markush group, spelling out the often expansive list of possible groups. In this manner, you get to use both the exactitude that a structural formula provides (i.e., what is claimed must have at least express structure as presented) with carefully specified variability by the lists of the Markush groups (using whatever definitions you’ve provided in the specification).
As we expand on the standard patent tactic of using Markush Groups and look specifically at their application in chemical patents, it’s worth noting that many modern chemical patents will eschew the exact Markush Groups phrase "selected from the group consisting of..." explained above to avoid the tediousness of how frequently the phrase would otherwise appear in a typical broad chemistry claim. Some are resorting to simply using “is” in all cases before enumerating options, but you might also see phrases like “selected from” (i.e., leaving out “from the group consisting of”), “chosen from,” or “represents.” In any case, all variants simply seek to fulfill the requirement of describing selection from a closed group of options. You can safely interpret these other terms as equivalent to the proper Markush Group phraseology, just with fewer words. Markush Structure Example
Look at this example of the Markush structure drawn for alpelisib in Pat. No. 8,476,268.
Here, the applicant has narrowed the molecule down to a fairly specific structure. The structural formula locks in the identity, connectivity, and stereochemistry of the three major ring systems and leaves only two variables R1 and R3. A fair amount of breadth, however, can be found in the definitions of these variables. Just take a look at that of R1:
That’s a lot of options, but it’s less than you think. It primarily specifies various alkyl chains and cyclic groups of certain sizes having only a limited set of further substitutions. Looking at the real molecule (shown below) the trifluoro-dimethylethyl group is indeed included there under option (1), but the claim covers so much more without resorting to claiming everything under the sun. Rather, they (presumably) claimed all the specific classes of variants that were of interest.
What goes in the structure versus the variables is the name of the game for patents in the chemical arts. Generally speaking, the structural formula presents the necessary scaffold for the drug or chemical while the variables contain all the options, whether there are two or two hundred. In situations when the structure is already quite narrow, the variable definitions might very well be trying to enumerate immense breadth rather than to further limit the claims. Therefore, paying attention to the structure and connectivity between the variables can often be more illuminating as to the boundaries of the scope. Chemical patents filed early in the drug discovery process may play this strategy a bit fast and loose because the applicant does not yet know what will be critical, but the game is the same. When trying to understand a chemical patent, carefully read through the variables as well as any definitions in the specification all the while noting their positions within the depicted structure.
Other Key Constructs Found in Chemical and Drug Patents
In addition to the above discussion, the following considerations and elements are often found in tandem with a Markush structure claim.
Portfolio Cornerstone for Drug and Chemical Companies
Although method of treatment and method of manufacture claims, not discussed here, can provide strong, alternative coverage (critically so in certain contexts), composition of matter claims, usually defined by a Markush structure, often function as the cornerstone of the portfolio for a drug or chemical company. Therefore, these claims are crafted in a style sometimes daunting in appearance but organized in a consistent manner compatible with the same tactics of breadth of specificity shared by all patents.
This primer will hopefully get you well on your way to clarifying and taking meaning from the chemical and drug patents on your reading list, but as always, don’t hesitate to reach out with more specific questions you may encounter along the way. Related Reading
This is Part 2 of an ongoing series focused on life science patents. If you found this valuable, we highly recommend checking our Part 1: Drug patents and the FDA: Timelines, Exclusivity, and Extensions. Later this month, we'll also being doing a podcast episode that takes a deep dive on fortifying your valuable life science patents.
|
Ashley Sloat, Ph.D.Startups have a unique set of patent strategy needs - so let this blog be a resource to you as you embark on your patent strategy journey. Archives
August 2022
Categories |
RSS Feed